Physician profile
Ebenezer Kb Odoom
NPI 1154416691
$5,350.54
in general payments reported to CMS, 2019-2025
23 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 92% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $545 · 2021: $695 · 2022: $581 · 2023: $640 · 2024: $868 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $993.25 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $943.42 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Pfizer INC. | $625.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $583.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $446.16 | 2022-2025 | |
| Amgen INC. | $292.14 | 2021-2025 | Repatha, Otezla, Otezla |
| Mannkind Corporation | $200.02 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $186.05 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $145.98 | 2021-2023 | |
| Amarin Pharma, INC. | $129.81 | 2019-2020 | |
| Dexcom, INC. | $125.36 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $99.89 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $75.66 | 2019-2024 | Xarelto |
| Ani Pharmaceuticals, INC. | $62.98 | 2025 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $56.75 | 2021-2022 | |
| Shield Therapeutics INC | $56.27 | 2023-2025 | Accrufer |
| Global Blood Therapeutics, INC. | $47.99 | 2021 | |
| Abbott Laboratories | $43.16 | 2022-2024 | Freestyle Libre 3 |
| Incyte Corporation | $42.22 | 2025 | Opzelura |
| Exact Sciences Corporation | $37.03 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $24.00 | 2024 | Voquezna |
| Astellas Pharma US INC | $18.41 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebenezer Odoom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.